Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine through distributorship or licensing, and supply agreements for the therapeutic areas, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry, family medicine, and general surgery. The Proprietary Brands segment develops, markets, and sells dermatological products and health supplement products. This segment offers dermocosmetic products under the Ceradan and TDF brands through medical professionals; health supplement products under the Ocean Health brand directly to consumers via retail channels; and scalp care products under the CG 210 brand through medical professionals. The Medical Hypermart and Digital segment wholesales pharmaceuticals and medical supplies for healthcare professionals and institutions, and retail pharmacies through tele-sales and sales representatives. The segment also operates an online B2B platform; and WellAway, an e-pharmacy. In addition, it offers PLINEST and NEWEST Polynucleotides-HPTTM products; OXITHION, a skin brightening solution; and Nabota, a highpurity botulinum toxin. Further, the company provides pharmaceutical products, nutraceuticals, and medical devices for hospitals, polyclinics, specialists, and general practitioners. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore. Show more